Vertex Pharmaceuticals Incorporated (VRTX) : The consensus on Vertex Pharmaceuticals Incorporated (VRTX) based on 13 analyst recommendation on the company stock is 1.58, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Vertex Pharmaceuticals Incorporated (VRTX) : Currently there are 12 street experts covering Vertex Pharmaceuticals Incorporated (VRTX) stock. The most bullish and bearish price target for the stock is $155 and $75 respectively for the short term. The average price target of all the analysts comes to $116.42. The estimated standard deviation from the target is $20.26.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Morgan Stanley maintains its rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The rating major has initiated the coverage with overweight rating on the shares. The Analysts at Morgan Stanley lowers the price target from $140 per share to $139 per share. The rating by the firm was issued on July 28, 2016.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): stock was range-bound between the intraday low of $95.17 and the intraday high of $96.685 after having opened at $95.8 on Wednesdays session. The stock finally closed in the red at $95.8, a loss of -0.19%. The stock remained in the red for the whole trading day. The total traded volume was 928,256 shares. The stock failed to cross $96.685 in Wednesdays trading. The stocks closing price on Thursday was $95.78.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.